Triumvira Immunologics

Developer of T-cell therapies for treating cancers

placeAustin, Texas, United States calendar_todayFounded 2015 groups85 employees language triumvira.com

Registered entities

Innovation

10 patent families (3 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace steady. Cited 573 times.

YearFilings
20202
20212
20224
20238
20248
20254

Investor mix

13 investors on record; lead investors include Leaps by Bayer, Northpond Ventures.

Investor typeCountShare
Venture capital862%
Private equity18%
Bank & private debt18%
Other / undisclosed323%
Coming soon